Hikma Pharmaceuticals Plc Company Profile (LON:HIK)

About Hikma Pharmaceuticals Plc (LON:HIK)

Hikma Pharmaceuticals Plc logoHikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company's segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets. The Company sells specialized generic injectable products across the globe. It also sells non-injectable generic products in the United States, supplying over 260 products in approximately 110 different dosage strengths and forms. The Company's other businesses comprise Arab Medical Containers, a manufacturer of plastic specialized medicinal sterile containers, International Pharmaceuticals Research Centre, which conducts bio-equivalency studies, and the active pharmaceutical ingredient (API) manufacturing division of Hikma Pharmaceuticals Limited Jordan.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Pharmaceuticals
  • Sub-Industry: N/A
  • Symbol: LON:HIK
  • CUSIP: N/A
  • Web: www.hikma.com/
Capitalization:
  • Market Cap: £2.7 billion
  • Outstanding Shares: 240,000,000
Average Prices:
  • 50 Day Moving Avg: GBX 1,261.41
  • 200 Day Moving Avg: GBX 1,631.70
  • 52 Week Range: GBX 1,101 - GBX 2,346
P/E:
  • Trailing P/E Ratio: 16.33
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: £1.96 billion
  • Price / Sales: 1.38
  • Book Value: GBX 10.17 per share
  • Price / Book: 1.11
Dividend:
  • Dividend Yield: 1.4%
Profitability:
  • EBIDTA: £451 million
  • Net Margins: 7.82%
  • Return on Equity: 5.69%
  • Return on Assets: 3.19%
Misc:
  • Average Volume: 752,830 shs.
 

Frequently Asked Questions for Hikma Pharmaceuticals Plc (LON:HIK)

What is Hikma Pharmaceuticals Plc's stock symbol?

Hikma Pharmaceuticals Plc trades on the London Stock Exchange (LON) under the ticker symbol "HIK."

How often does Hikma Pharmaceuticals Plc pay dividends? What is the dividend yield for Hikma Pharmaceuticals Plc?

Hikma Pharmaceuticals Plc announced a dividend on Wednesday, March 15th. Stockholders of record on Thursday, April 6th will be given a dividend of GBX 0.22 per share on Thursday, May 25th. This represents a dividend yield of 0.78%. The ex-dividend date of this dividend is Thursday, April 6th. This is a positive change from Hikma Pharmaceuticals Plc's previous dividend of $0.21. The official announcement can be seen at this link. View Hikma Pharmaceuticals Plc's Dividend History.

Where is Hikma Pharmaceuticals Plc's stock going? Where will Hikma Pharmaceuticals Plc's stock price be in 2017?

11 equities research analysts have issued 1 year target prices for Hikma Pharmaceuticals Plc's stock. Their predictions range from GBX 1,045 to GBX 2,431. On average, they expect Hikma Pharmaceuticals Plc's stock price to reach GBX 1,574.18 in the next year. View Analyst Ratings for Hikma Pharmaceuticals Plc.

Who are some of Hikma Pharmaceuticals Plc's key competitors?

Who are Hikma Pharmaceuticals Plc's key executives?

Hikma Pharmaceuticals Plc's management team includes the folowing people:

  • Said Darwazah, Chairman of the Board, Chief Executive
  • Mazen Samih Talib Darwazah, Executive Vice Chairman of the Board, President and Chief Executive Officer of MENA and Emerging Markets
  • Khalid Nabilsi, Chief Financial Officer
  • Brian Hoffman, President, West-Ward Pharmaceuticals
  • Michael Raya, Chief Executive Officer, West-Ward Pharmaceuticals
  • Majda Labadi, Corporate Vice President - Human Resources and Head of Operations, MENA
  • Riad Mishlawi, EU Vice President and Global Head - Injectables
  • Susan Ringdal, Vice President - Corporate Strategy and Investor Relations
  • Hussein Arkhagha, General Counsel
  • Bassam Wael Rushdi Kanaan, Chief Strategy and Corporate Development Officer

How do I buy Hikma Pharmaceuticals Plc stock?

Shares of Hikma Pharmaceuticals Plc and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Hikma Pharmaceuticals Plc's stock price today?

One share of Hikma Pharmaceuticals Plc stock can currently be purchased for approximately GBX 1,127.


MarketBeat Community Rating for Hikma Pharmaceuticals Plc (LON HIK)
Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  389 (Vote Outperform)
Underperform Votes:  179 (Vote Underperform)
Total Votes:  568
MarketBeat's community ratings are surveys of what our community members think about Hikma Pharmaceuticals Plc and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Hikma Pharmaceuticals Plc (LON:HIK) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 8 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.09)
Consensus Price Target: GBX 1,574.18

Analysts' Ratings History for Hikma Pharmaceuticals Plc (LON:HIK)
Show:
DateFirmActionRatingPrice TargetDetails
8/29/2017Stifel NicolausDowngradeHoldGBX 2,300 -> GBX 1,320View Rating Details
8/25/2017Barclays PLCLower Price TargetOverweightGBX 2,200 -> GBX 1,500View Rating Details
8/24/2017Citigroup Inc.Reiterated RatingNeutralGBX 1,350View Rating Details
8/22/2017Goldman Sachs Group, Inc. (The)DowngradeNeutralGBX 2,600 -> GBX 1,310View Rating Details
8/21/2017Morgan StanleyDowngradeEqual weightGBX 1,600 -> GBX 1,350View Rating Details
8/21/2017Jefferies Group LLCLower Price TargetHoldGBX 1,390 -> GBX 1,045View Rating Details
8/17/2017Numis Securities LtdReiterated RatingAddGBX 1,560View Rating Details
8/17/2017Peel HuntReiterated RatingHoldGBX 2,150View Rating Details
7/4/2017HSBC Holdings plcReiterated RatingReduceGBX 1,800View Rating Details
6/27/2017J P Morgan Chase & CoReiterated RatingNeutralGBX 1,500View Rating Details
11/30/2016AlphaValueReiterated RatingBuyGBX 2,431View Rating Details
3/16/2016Panmure GordonUpgradeBuyGBX 2,120View Rating Details
(Data available from 9/25/2015 forward)

Earnings

Earnings History for Hikma Pharmaceuticals Plc (LON:HIK)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Hikma Pharmaceuticals Plc (LON:HIK)
Current Year EPS Consensus Estimate: $1.07 EPS

Dividends

Dividend History by Quarter for Hikma Pharmaceuticals Plc (LON HIK)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
3/15/2017€0.220.78%4/6/20174/6/20175/25/2017
3/11/2015€0.210.64%4/16/20154/16/20155/21/2015
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Hikma Pharmaceuticals Plc (LON:HIK)
Insider Trades by Quarter for Hikma Pharmaceuticals Plc (LON:HIK)
Insider Trades by Quarter for Hikma Pharmaceuticals Plc (LON:HIK)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/19/2016Ali Al-HusryInsiderBuy50,000GBX 1,790£895,000
12/16/2016Mazen DarwazahInsiderBuy90,730GBX 1,849£1,677,597.70
12/12/2016Ali Al-HusryInsiderBuy50,000GBX 1,707£853,500
12/9/2016Ali Al-HusryInsiderBuy50,000GBX 1,723£861,500
12/6/2016Ali Al-HusryInsiderBuy100,000GBX 1,682£1,682,000
12/5/2016Ali Al-HusryInsiderBuy50,000GBX 1,674£837,000
12/2/2016Mazen DarwazahInsiderBuy50,000GBX 1,662£831,000
12/1/2016Mazen DarwazahInsiderBuy50,000GBX 1,674£837,000
11/30/2016Said DarwazahInsiderBuy50,000GBX 1,662£831,000
9/28/2016Said DarwazahInsiderBuy10,000GBX 2,085£208,500
9/27/2016Ali Al-HusryInsiderBuy50,000GBX 2,094£1,047,000
9/26/2016Said DarwazahInsiderBuy50,000GBX 2,078£1,039,000
9/23/2016Ali Al-HusryInsiderBuy50,000GBX 2,099£1,049,500
9/21/2016Ali Al-HusryInsiderBuy50,000GBX 2,138£1,069,000
9/16/2016Al-Husry,AliInsiderBuy50,000GBX 2,119£1,059,500
9/15/2016Darwazah,SaidInsiderBuy70,251GBX 2,122£1,490,726.22
9/8/2016Darwazah,MazenInsiderBuy150,000GBX 2,162£3,243,000
9/6/2016Darwazah,MazenInsiderBuy155,991GBX 2,194£3,422,442.54
8/31/2016Al-Husry,AliInsiderBuy140,000GBX 2,150£3,010,000
8/26/2016Darwazah,SaidInsiderBuy200,000GBX 2,160£4,320,000
6/24/2016Darwazah,MazenInsiderBuy150,000GBX 2,200£3,300,000
6/17/2016Al-Husry,AliInsiderBuy70,000GBX 22£15,400
5/9/2016Darwazah,SaidInsiderBuy17,440GBX 2,228£388,563.20
4/26/2016Darwazah,SaidInsiderBuy10,000GBX 2,260£226,000
4/25/2016Darwazah,SaidInsiderBuy10,000GBX 2,324£232,400
4/22/2016Darwazah,SaidInsiderBuy30,000GBX 2,325£697,500
4/20/2016Darwazah,SaidInsiderBuy30,000GBX 2,271£681,300
4/19/2016Darwazah,SaidInsiderBuy30,000GBX 2,266£679,800
4/11/2016J. Castellani,JohnInsiderBuy2,500GBX 2,103£52,575
4/7/2016Darwazah,MazenInsiderBuy60,000GBX 2,118£1,270,800
4/5/2016Darwazah,SaidInsiderBuy30,000GBX 2,055£616,500
3/31/2016Darwazah,SaidInsiderBuy30,000GBX 1,972£591,600
3/24/2016Butler,PatInsiderBuy2,500GBX 1,920£48,000
3/21/2016Pickering ,RobertInsiderBuy2,500GBX 1,856£46,400
8/27/2015Kirby,PamelaInsiderBuy3,317GBX 2,264£75,096.88
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Hikma Pharmaceuticals Plc (LON:HIK)
Latest Headlines for Hikma Pharmaceuticals Plc (LON:HIK)
Source:
DateHeadline
americanbankingnews.com logoHikma Pharmaceuticals Plc (HIK) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - September 16 at 6:56 AM
morningstar.co.uk logoEXTRA: Vectura Posts Pretax Loss Increase Due To Amortisation Costs
www.morningstar.co.uk - September 6 at 7:23 PM
finance.yahoo.com logoETFs with exposure to Hikma Pharmaceuticals Plc : August 29, 2017
finance.yahoo.com - August 29 at 8:00 PM
americanbankingnews.com logoHikma Pharmaceuticals Plc (HIK) Downgraded by Stifel Nicolaus
www.americanbankingnews.com - August 29 at 6:38 AM
americanbankingnews.com logoHikma Pharmaceuticals Plc's (HIK) "Neutral" Rating Reaffirmed at Citigroup Inc.
www.americanbankingnews.com - August 28 at 12:56 AM
americanbankingnews.com logoHikma Pharmaceuticals Plc (HIK) Price Target Lowered to GBX 1,500 at Barclays PLC
www.americanbankingnews.com - August 27 at 8:50 AM
finance.yahoo.com logo[$$] Drug stocks shine as FTSE 100 drifts lower
finance.yahoo.com - August 26 at 5:25 AM
finance.yahoo.com logoHikma Pharmaceuticals Plc : HIK-GB: Dividend Analysis : August 25th, 2017 (record date) : By the numbers : August 26, 2017
finance.yahoo.com - August 26 at 5:25 AM
finance.yahoo.com logoPropeller Health Announces Expansion of Digital Health Collaboration with GlaxoSmithKline to Improve Management of Asthma and COPD
finance.yahoo.com - August 24 at 7:28 AM
reuters.com logoUK Stocks-Factors to watch on Aug 21 - Reuters
www.reuters.com - August 22 at 9:07 PM
finance.yahoo.com logoHikma Pharmaceuticals Plc :HIK-GB: Earnings Analysis: For the six months ended June 30, 2017 : August 22, 2017
finance.yahoo.com - August 22 at 9:07 PM
americanbankingnews.com logoHikma Pharmaceuticals Plc (HIK) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - August 22 at 6:44 AM
finance.yahoo.com logoJazz on the Street: Analysts’ Recommendations for JAZZ in August
finance.yahoo.com - August 21 at 6:45 PM
finance.yahoo.com logo[$$] Imperial sighs after broker waves away vaping scepticism
finance.yahoo.com - August 21 at 6:45 PM
americanbankingnews.com logoHikma Pharmaceuticals Plc (HIK) Price Target Lowered to GBX 1,045 at Jefferies Group LLC
www.americanbankingnews.com - August 21 at 4:46 PM
americanbankingnews.com logoMorgan Stanley Lowers Hikma Pharmaceuticals Plc (HIK) to Equal weight
www.americanbankingnews.com - August 21 at 6:06 AM
reuters.com logoDrugmaker Hikma's US unit raises medicine prices: Financial Times - Reuters
www.reuters.com - August 20 at 5:48 PM
americanbankingnews.com logoHikma Pharmaceuticals Plc (HIK) Earns "Hold" Rating from Peel Hunt
www.americanbankingnews.com - August 20 at 5:02 PM
americanbankingnews.com logoHikma Pharmaceuticals Plc (HIK) Stock Rating Reaffirmed by Numis Securities Ltd
www.americanbankingnews.com - August 20 at 3:44 PM
marketwatch.com logoHikma sees tough competition in generics market
www.marketwatch.com - August 18 at 7:17 PM
fool.co.uk logoHikma Pharmaceuticals plc’s pain could be GlaxoSmithKline plc’s gain
www.fool.co.uk - August 18 at 7:17 PM
seekingalpha.com logoHikma Pharmaceuticals plc. 2017 Q2 - Results - Earnings Call Slides
seekingalpha.com - August 18 at 7:17 PM
News IconUPDATE 1-UK Stocks-Factors to watch on Aug 17 - Business Insider
www.businessinsider.com - August 18 at 4:02 AM
finance.yahoo.com logo[$$] Hikma shares hit by generics business setback
finance.yahoo.com - August 18 at 4:02 AM
finance.yahoo.com logoDrugmaker Hikma trims sales forecasts, shares fall
finance.yahoo.com - August 18 at 4:02 AM
finance.yahoo.com logoEdited Transcript of HIK.L earnings conference call or presentation 17-Aug-17 8:30am GMT
finance.yahoo.com - August 18 at 4:02 AM
seekingalpha.com logoMylan Suffers From Jet Lag
seekingalpha.com - August 15 at 8:04 PM
americanbankingnews.com logoHikma Pharmaceuticals Plc's (LON:HIK) Add Rating Reaffirmed at Numis Securities Ltd
www.americanbankingnews.com - August 13 at 10:32 PM
americanbankingnews.com logoHikma Pharmaceuticals Plc (LON:HIK) Scheduled to Post Earnings on Thursday
www.americanbankingnews.com - August 10 at 1:20 AM
bizjournals.com logoTOP OF THE LIST: Largest Ohio mergers and acquisitions - Columbus Business First
www.bizjournals.com - July 28 at 10:20 PM
americanbankingnews.com logoHikma Pharmaceuticals Plc (LON:HIK) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - July 28 at 7:41 AM
zacks.com logoWhat Lies in Store for Glaxo (GSK) this Earnings Season?
www.zacks.com - July 21 at 3:52 AM
americanbankingnews.com logoHSBC Holdings plc Reaffirms Reduce Rating for Hikma Pharmaceuticals Plc (HIK)
www.americanbankingnews.com - July 4 at 10:58 PM
americanbankingnews.com logoHikma Pharmaceuticals Plc (HIK) Given Overweight Rating at Barclays PLC
www.americanbankingnews.com - July 3 at 1:33 PM
americanbankingnews.com logoHikma Pharmaceuticals Plc (HIK) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - July 3 at 11:01 AM
americanbankingnews.com logoCitigroup Inc. Reiterates "Neutral" Rating for Hikma Pharmaceuticals Plc (HIK)
www.americanbankingnews.com - June 28 at 9:00 AM
americanbankingnews.com logoHikma Pharmaceuticals Plc (HIK) Given New GBX 1,390 Price Target at Jefferies Group LLC
www.americanbankingnews.com - June 28 at 9:00 AM
marketwatch.com logoHikma to split U.S. business; CEO Raya to depart - MarketWatch - MarketWatch
www.marketwatch.com - June 26 at 4:25 AM
seekingalpha.com logoJazz Pharmaceuticals Is A Strong Buy With Potential FDA Approvals
seekingalpha.com - June 15 at 7:54 PM
reuters.com logoBRIEF-Hikma signs license, supply agreement for Octaplex‍
www.reuters.com - May 31 at 5:36 PM
americanbankingnews.com logoJPMorgan Chase & Co. Reiterates "Neutral" Rating for Hikma Pharmaceuticals Plc (HIK)
www.americanbankingnews.com - May 22 at 7:00 PM
News IconUPDATE 1-UK Stocks-Factors to watch on May 19
www.businessinsider.com - May 20 at 9:58 AM
morningstar.co.uk logoTOP NEWS: Hikma Pharmaceuticals Trims Revenue Outlook On Generics
www.morningstar.co.uk - May 19 at 5:25 PM
rttnews.com logoHikma Pharmaceuticals Cuts FY Revenue Outlook
www.rttnews.com - May 19 at 5:25 PM
marketwatch.com logoHikma cuts revenue guidance for 2017
www.marketwatch.com - May 19 at 5:25 PM
thestreet.com logoHikma Trims Full Year Revenue Guidance After Advair Diskus Delay - TheStreet.com
www.thestreet.com - May 19 at 10:13 AM
americanbankingnews.com logoHikma Pharmaceuticals Plc (HIK) Downgraded by Numis Securities Ltd to "Add"
www.americanbankingnews.com - May 19 at 9:00 AM
americanbankingnews.com logoHikma Pharmaceuticals Plc (HIK) Downgraded by Jefferies Group LLC to "Underperform"
www.americanbankingnews.com - May 18 at 7:46 PM
americanbankingnews.com logoJPMorgan Chase & Co. Lowers Hikma Pharmaceuticals Plc (HIK) Price Target to GBX 1,800
www.americanbankingnews.com - May 12 at 9:32 PM
thestreet.com logoHikma Shares Plunge After It Says 'Low Likelihood' of 2017 Generic Advair Approval - TheStreet.com
www.thestreet.com - May 12 at 6:20 PM

Social

Social activity is not available for this stock.

Chart

Hikma Pharmaceuticals Plc (HIK) Chart for Monday, September, 25, 2017

This page was last updated on 9/25/2017 by MarketBeat.com Staff